TIVDAK (Tisotumab Vedotin) — ADC for Recurrent Cervical Cancer
July 15, 2026
TIVDAK is a Tissue Factor-targeting ADC, opening a new option for patients with recurrent or metastatic cervical cancer after prior chemotherapy.
What is TIVDAK?
TIVDAK (Tisotumab vedotin-tftv) is an ADC targeting Tissue Factor (TF) — a protein highly expressed on cervical cancer cells. The antibody delivers vedotin (MMAE) to TF+ cells, disrupting the microtubule structure and causing cancer cell death.
Indication
TIVDAK is FDA-approved for recurrent or metastatic cervical cancer that has progressed after at least one prior chemotherapy regimen. It is an important option for patients no longer responding to Carboplatin + Paclitaxel or Pembrolizumab.
In China
Recurrent cervical cancer is a difficult-to-treat challenge in China. Next-generation ADCs like TIVDAK are being accessed at major research centres and through the Hainan Free Trade Zone for international patients.
Disclaimer
Information is for reference only. Gynaecologic oncologists determine the indication after full assessment.
Related Images
